BMN 673 (CAS 1207454-56-5)
QUICK LINKS
BMN 673, known by its developmental code, is a small molecule with significant interest in the field of biochemistry. It is particularly known for its role as a potent inhibitor of the enzyme poly (ADP-ribose) polymerase (PARP). PARP inhibitors like BMN 673 have garnered attention for their ability to interfere with one of the pathways cells use to repair damaged DNA. By inhibiting PARP activity, these compounds can increase the accumulation of DNA breaks, leading to cell death in cells that rely heavily on PARP for DNA repair. In research, BMN 673 can be used as a tool compound to elucidate the pathways involved in DNA repair and the cellular response to DNA damage. Its potent inhibitory action on PARP makes it a valuable agent for investigating the role of PARP in various biological processes, including transcription regulation, cell death pathways, and the maintenance of genomic integrity.
BMN 673 (CAS 1207454-56-5) References
- Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. | Murai, J., et al. 2014. Mol Cancer Ther. 13: 433-43. PMID: 24356813
- Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer. | Duan, W., et al. 2014. Front Oncol. 4: 368. PMID: 25566506
- Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. | Yin, Y., et al. 2017. Am J Cancer Res. 7: 473-483. PMID: 28401005
- Synthetic lethal targeting of RNF20 through PARP1 silencing and inhibition. | Guppy, BJ. and McManus, KJ. 2017. Cell Oncol (Dordr). 40: 281-292. PMID: 28462496
- PARP Inhibition Combined With Thoracic Irradiation Exacerbates Esophageal and Skin Toxicity in C57BL6 Mice. | Lourenco, LM., et al. 2018. Int J Radiat Oncol Biol Phys. 100: 767-775. PMID: 29413287
- Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks. | Soni, A., et al. 2018. Mol Cancer Ther. 17: 2206-2216. PMID: 29970481
- High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects. | Li, X., et al. 2018. EBioMedicine. 38: 47-56. PMID: 30472087
- Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. | Papp, E., et al. 2018. Cell Rep. 25: 2617-2633. PMID: 30485824
- Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent. | Toma, M., et al. 2018. Oncotarget. 9: 36867-36877. PMID: 30627327
- BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor. | Zhang, P., et al. 2019. Int J Biol Sci. 15: 1942-1954. PMID: 31523195
- XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a. | Wang, J., et al. 2021. Cancer Lett. 503: 197-212. PMID: 33493586
- PARP inhibitor BMN-673 induced apoptosis by trapping PARP-1 and inhibiting base excision repair via modulation of pol-β in chromatin of breast cancer cells. | Sethy, C. and Kundu, CN. 2022. Toxicol Appl Pharmacol. 436: 115860. PMID: 34998856
- PTEN Loss Enhances Error-Prone DSB Processing and Tumor Cell Radiosensitivity by Suppressing RAD51 Expression and Homologous Recombination. | Pei, X., et al. 2022. Int J Mol Sci. 23: PMID: 36361678
- BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy. | Soni, A., et al. 2022. Cancers (Basel). 14: PMID: 36428712
- Combination of PARP and WEE1 inhibitors in vitro: Potential for use in the treatment of SHH medulloblastoma. | Lukoseviciute, M., et al. 2023. Oncol Rep. 49: PMID: 37144508
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BMN 673, 5 mg | sc-503859 | 5 mg | $340.00 |